Cargando…
SAT-429 Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy
Context The dual antiproliferative mechanism of mycophenolate appears to be beneficial in Graves’ orbitopathy (GO). Methods The safety data, which is of utmost importance in immunomodulation, from the two major randomized mycophenolate trials [“Chinese trial” (1) and “European Group on Graves’ Orbit...
Autores principales: | Lee, Alan C H, Diana, Tanja, Frommer, Lara, Kahaly, George Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208131/ http://dx.doi.org/10.1210/jendso/bvaa046.139 |
Ejemplares similares
-
SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019) -
SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model
por: Diana, Tanja, et al.
Publicado: (2019) -
SAT-606 Graves' Orbitopathy Treated with Kahaly's Protocol: IV High Dose Glucocorticoids
por: Patel, Bijal, et al.
Publicado: (2019) -
SAT-421 Novel Role of Chloroquine and Hydroxychloroquine in Graves’ Orbitopathy Therapy by Targeting Orbital Fibroblasts
por: Guo, Yan, et al.
Publicado: (2020) -
OR18-03 Functional TSH Receptor Antibodies Are a Biomarker for Graves’ Disease - a Prospective Trial
por: Kahaly, George Jean, et al.
Publicado: (2020)